Roivant Sciences Director Melissa Epperly Receives Routine Stock Grant
Roivant Sciences Ltd.
Subscribe to track ROIV
Premium users can add ticker alerts and receive realtime notification updates.
Filing Summary
Roivant Sciences Ltd. ($ROIV) - Form 4 Filing Update
Insider: Melissa B. Epperly (Director) Transaction Date: October 23, 2026 Details:
- Acquired: 513 Common Shares at $0.00 (Director Compensation Plan grant)
- Disposed (Withheld for Taxes): 116 Common Shares at $36.49 ($4,232.84)
- Net Change: +397 Common Shares
- Post-Transaction Holdings: 15,351 Common Shares (Direct) Significance: Low (Routine director compensation and tax withholding)
Comprehensive Analysis
Executive Summary
On October 27, 2026, Roivant Sciences Ltd. ($ROIV) filed a Form 4 on behalf of Director Melissa B. Epperly. The filing reports routine equity compensation received pursuant to the Issuer's Non-Employee Director Compensation Plan on October 23, 2026.
Transaction Breakdown
- Stock Award (Code A): Ms. Epperly received a grant of 513 fully vested Common Shares at $0.00 per share.
- Tax Withholding (Code F): 116 Common Shares were net-settled and withheld by the company at a price of $36.49 per share ($4,232.84 total value) to satisfy tax withholding liabilities associated with the grant.
- Net Addition: 397 Common Shares added to direct holdings.
- Ending Ownership: 15,351 Common Shares held directly.
Market & Trading Significance
This transaction carries Low significance for investors. It reflects standard, scheduled non-employee director compensation rather than an open-market purchase or discretionary insider sale.
Get Real-Time Alerts
Join our community to receive instant notifications when high-significance filings are published
Important Disclaimer
This content is drawn from public SEC filings and may contain errors. It is for informational purposes only and is not investment, legal, or tax advice.
Nothing here is a recommendation to buy, sell, or hold any security. Do your own due diligence.